Fourteen @entity2275 @entity1 were submitted to treatment with @entity4444 . They were endoscopically controlled before the beginning of treatment and at the third and sixth week. In the first phase of the investigation, @entity4444 was given in a dosage of 1.0 g/day. At the end of the 3rd week, those @entity1 who showed a reduction of less than 50% on the size of the @entity1066 had the @entity4444 doses increased to 1.6 g/day. The second phase started with nine @entity1 which healed at the end of the six weeks. These @entity1 were randomly allocated to two groups in a double blind trial involving @entity4444 (600 mg/day) or placebo for 12 weeks. At the end of this period, the @entity1 were submitted to an endoscopic control. Two @entity1 in the placebo group had a recurrence of their @entity1066 . This did not happen to any of the @entity1 taking @entity4444 . Two and a half months after stopping their maintenance treatment, two @entity1 of the @entity4444 group had a recurrence of their lesions.

[ @entity4444 in the treatment of XXXX ].

@entity1 :: ('9606', 'Species') :: ['patients'] @entity1066 :: ('MESH:D014456', 'Disease') :: ['ulcer', 'ulcers'] @entity4444 :: ('MESH:D002927', 'Chemical') :: ['cimetidine', 'Cimetidine'] @entity2275 :: ('MESH:D013276', 'Disease') :: ['gastric ulcer']
@entity2275 :: (MESH:D013276,Disease) :: ['gastric ulcer']
